RYTM
Rhythm Pharmaceuticals Inc
NASDAQ · Biotechnology
$103.61
-0.26 (-0.25%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 142.37M | 975.71M | 873.25M | 945.71M |
| Net Income | -285,129,788 | -22,144,056 | -23,253,892 | -24,310,165 |
| EPS | — | — | — | — |
| Profit Margin | -200.3% | -2.3% | -2.7% | -2.6% |
| Rev Growth | +245.7% | -2.7% | +8.2% | +7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.38B | 1.47B | 1.46B | 1.63B |
| Total Equity | 2.07B | 3.68B | 4.04B | 3.52B |
| D/E Ratio | 0.67 | 0.40 | 0.36 | 0.46 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -286,331,037 | -26,213,634 | -24,112,007 | -26,719,532 |
| Free Cash Flow | — | -20,824,615 | -25,629,049 | -24,210,481 |